Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Wino115on Jun 17, 2021 9:22am
169 Views
Post# 33401092

Website Oncology Articles

Website Oncology Articles

The website is definitely an improvement if for no other reason than it has a library of their webcasts and important articles, both of which were limited in the last iteration.

My two suggestions would be they should add in some of the other important presentations they've done in the past, like R&D days, etc (provided they are still accurate statements).

Secondly, I noticed that most of the Sortilin papers are limited to only the ones the Montreal team did and there's not anything from, say, the Univ Gothenburg doctors who just published one on breast cancer, and the one on pancreatic from a different research team.  Both of those would lend additional credence to the Sortilin approach and they had some very strong analytical data in them too.  They should not be limiting the research papers to only those the Montreal team have written especially when the others are very powerful papers.

Its sort of the same in hepatology, 90% are from the Grinspoon lab.  In that case, I don't recall a lot of papers NOT coming from his research so that's more understandable.  But having outside validation of your pipeline science is a big credibility booster.  

All-in though, it's a great start and hopefully they can incorporate the hard data in a very illuminating way.   They should also think about stuff like a Q and A, either video or written, with Marsoulis, PL or KOLs on specifics in the programs.  For instance, something like "The importance of Vascular Mimicry: what is it and what we have seen so far."   Topics like that to help explain the science in simpler terms.   Have a library of these little chats And update them every so often.

 

<< Previous
Bullboard Posts
Next >>